Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synageva BioPharma, a discoverer, developer of therapies for patients with rare conditions and unmet medical need, and to-BBB have signed a research pact to investigate the potential of transporting therapeutic proteins throughout the blood-brain barrier into the central nervous system (CNS).
Subscribe to our email newsletter
The companies said that the new collaboration will support the development program of therapies that caters to multiple rare diseases such as, lysosomal storage diseases (LSDs).
Synageva R&D head and chief medical officer Anthony Quinn said that this collaboration, which combines Synageva’s proprietary compounds and technology with to-BBB’s expertise in CNS delivery, provides Synageva with an opportunity to extend the therapeutic benefits of their pipeline products targeting rare diseases with CNS manifestations.